ODI — Odi Pharma AB (publ) Income Statement
0.000.00%
Last trade - 00:00
- SEK86.75m
- SEK80.23m
- SEK0.14m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0.313 | 0.139 |
Cost of Revenue | |||||
Gross Profit | — | — | — | -0.104 | -0.718 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.34 | 4.93 | 3.96 | 7.52 | 6.95 |
Operating Profit | -3.34 | -4.93 | -3.96 | -7.21 | -6.81 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -3.35 | -4.94 | -3.97 | -7.24 | -6.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.63 | -4.96 | -3.98 | -7.24 | -6.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.63 | -4.96 | -3.98 | -7.24 | -6.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.63 | -4.96 | -3.98 | -7.24 | -6.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.29 | -0.36 | -0.26 | -0.476 | -0.453 |
Dividends per Share |